PMID- 12954370
OWN - NLM
STAT- MEDLINE
DCOM- 20040503
LR  - 20190624
IS  - 0014-2999 (Print)
IS  - 0014-2999 (Linking)
VI  - 475
IP  - 1-3
DP  - 2003 Aug 15
TI  - Dilazep and fenofibric acid inhibit MCP-1 mRNA expression in glycoxidized 
      LDL-stimulated human endothelial cells.
PG  - 139-47
AB  - We previously reported that glycoxidized low-density lipoprotein (glycoxidized 
      LDL) enhanced monocyte chemoattractant protein-1 (MCP-1) mRNA expression through 
      activation of nuclear factor-kappaB (NF-kappaB). Here we investigated the effects 
      of dilazep, an anti-platelet agent, and fenofibric acid, an active metabolite of 
      fenofibrate, on glycoxidized low-density lipoprotein-(LDL)-enhanced MCP-1 mRNA 
      expression. Both 10 microg/ml dilazep and 100 microM fenofibric acid abrogated 
      MCP-1 mRNA expression. ZM241385, an A2a adenosine receptor antagonist, partially 
      inhibited the suppressive effect of dilazep. NF-kappaB activity was also 
      suppressed by 1 microg/ml dilazep and 10 microM fenofibric acid. The 
      antioxidative activity of these drugs on glycation to native LDL or oxidation to 
      glycated LDL was measured using lipid peroxidation and lyso-phosphatidylcholine 
      contents in LDL. Dilazep but not fenofibric acid exhibited antioxidative 
      activity. Although the mechanisms of anti-atherogenic effects of the two drugs on 
      glycoxidized LDL are different, both dilazep and fenofibric acid could 
      potentially prevent atherosclerosis in diabetes mellitus.
FAU - Sonoki, Kazuo
AU  - Sonoki K
AD  - Department of Medicine and Clinical Science, Graduate School of Medical Sciences, 
      Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka 812-8582, Japan.
FAU - Iwase, Masanori
AU  - Iwase M
FAU - Iino, Kenzo
AU  - Iino K
FAU - Ichikawa, Kojiro
AU  - Ichikawa K
FAU - Yoshinari, Mototaka
AU  - Yoshinari M
FAU - Ohdo, Shigehiro
AU  - Ohdo S
FAU - Higuchi, Shun
AU  - Higuchi S
FAU - Iida, Mitsuo
AU  - Iida M
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Chemokine CCL2)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Glycolates)
RN  - 0 (RNA, Messenger)
RN  - 0WT12SX38S (glycolic acid)
RN  - BGF9MN2HU1 (fenofibric acid)
RN  - F8KLC2BD5Z (Dilazep)
RN  - U202363UOS (Fenofibrate)
SB  - IM
MH  - Cells, Cultured
MH  - Chemokine CCL2/*antagonists & inhibitors/biosynthesis/genetics
MH  - Cholesterol, LDL/*pharmacology
MH  - Dilazep/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Endothelial Cells/*drug effects/metabolism
MH  - Endothelium, Vascular/drug effects/metabolism
MH  - Fenofibrate/*analogs & derivatives/*pharmacology
MH  - Gene Expression Regulation/drug effects/physiology
MH  - Glycolates/pharmacology
MH  - Humans
MH  - RNA, Messenger/*antagonists & inhibitors/biosynthesis/genetics
EDAT- 2003/09/05 05:00
MHDA- 2004/05/05 05:00
CRDT- 2003/09/05 05:00
PHST- 2003/09/05 05:00 [pubmed]
PHST- 2004/05/05 05:00 [medline]
PHST- 2003/09/05 05:00 [entrez]
AID - S0014299903021095 [pii]
AID - 10.1016/s0014-2999(03)02109-5 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2003 Aug 15;475(1-3):139-47. doi: 10.1016/s0014-2999(03)02109-5.